• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Clinical article has been accepted for publication - UnoMeter[TM] Safeti[TM] Max

OBSRVRegulatory press release20.08.2026 klo 15.59
Oslo, 20 August 2026 - Observe Medical ASA (the "Company" or "Observe Medical")
is pleased to announce that an article with clinical relevant data related to
the Company's UnoMeter[TM] Safeti[TM] Max has been accepted for publication by
 Journal of the Healthcare Infection
Society (https://www.his.org.uk/): Infection Prevention in Practice (IPIP), an
open access companion title to the respected Journal of Hospital
Infection (https://www.journals.elsevier.com/journal-of-hospital-infection), in
Journal of Hospital Infection.

The article "Evaluation of retrograde bacterial migration in a prototype urinary
drainage system with a silicone oil barrier" has been authored by Martin
Slettengren M.D. PhD. and Professor Jan Van Der Linden, M.D., Ph.D. of
Karolinska Institutet, Stockholm, and has been peer-reviewed by independent
experts in the relevant field.

The Company believes that this acceptance represents an important scientific
validation of its technology and supports the continued commercial development
of the UnoMeter[TM] portfolio. "Our ambition is to take clinical leadership
within the product category and with this publication, together with an earlier
publication, we now have a solid foundation to support the clinical performance
and the health-economic advantages of the recently launched UnoMeter[TM]
Safeti[TM] Max. Our position is unique as no other products in the market offer
documented clinical data and we see that we are in a strong position to continue
our commercial journey. The results are based on the UnoSafeCoat[ TM]
 technology and they further strengthen the scientific foundation for
commercialising the digital solution UnoMeter[TM] Sippi®, and our confidence in
the platform's long-term potential."

For further information, please contact:

Jørgen Mann, CEO Observe Medical
Mobile: +45 408 67558
E-mail: jorgen.mann@observemedical.com

Johan Fagerli, CFO Observe Medical
Mobile: +47 958 12765
E-mail: johan.fagerli@observemedical.com

About Observe Medical

Observe Medical is a Nordic medtech company that develops, markets and sells
innovative medtech products for the global market. The Company is committed to
improving patient welfare and patient outcomes, improving clinical data accuracy
and promoting positive health economics.

The Company seeks to drive growth by leveraging its expertise in sales and
commercialization of its broad portfolio of medical technology products, mainly
in urine measurement and ultrasound, in combination with targeted M&A and
distribution. Observe Medical is working with a network of leading distributors
to provide outstanding solutions for healthcare professionals globally.

The Company is headquartered in Oslo, Norway.

Further information is available atwww.observemedical.com.
\, Norway.\
\
Further information is available atwww.observemedical.com.\